

Supporting Information

Stereochemistries of mariannamides C and D, two lipohexapeptides, isolated from *Mariannaea elegans* NBRC102301

Kan'ichiro Ishiuchi^{a, *}, Akiho Nagumo^a, Mitsuyasu Kawaguchi^b, Honoka Furuyashiki^b,
Hidehiko Nakagawa^b, and Dai Hirose^c

a: Graduate School of Pharmaceutical Sciences, Nagoya-City University, 3-1, Tanabe-Dori, Mizuho-ku, Nagoya 467-8603, Aichi, Japan; b: Department of Organic and Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1, Tanabe-dori, Mizuho-ku, Nagoya 467-8603, Aichi, Japan; c: School of Pharmacy, Nihon University, 7-7-1, Narashinodai, Funabashi 274-8555, Chiba, Japan. E-mail: ishiuchi@phar.nagoya-cu.ac.jp

Table of Contents	page
Figure S1. ¹ H NMR spectrum of mariannamide C (1) in CDCl ₃ (500 MHz).	2
Figure S2. ¹³ C NMR spectrum of mariannamide C (1) in CDCl ₃ (125 MHz).	3
Figure S3. ¹ H- ¹ H COSY spectrum of mariannamide C (1) in CDCl ₃ .	4
Figure S4. HSQC spectrum of mariannamide C (1) in CDCl ₃ .	5
Figure S5. HMBC spectrum of mariannamide C (1) in CDCl ₃ .	6
Figure S6. ¹ H NMR spectrum of mariannamide D (2) in CDCl ₃ (500MHz).	7
Figure S7. ¹³ C NMR spectrum of mariannamide D (2) in CDCl ₃ (125MHz).	8
Figure S8. ¹ H- ¹ H COSY spectrum of mariannamide D (2) in CDCl ₃ .	9
Figure S9. HSQC spectrum of mariannamide D (2) in CDCl ₃ .	10
Figure S10. HMBC spectrum of mariannamide D (2) in CDCl ₃ .	11
Figure S11. Selected 2D NMR correlations for mariannamide D (2).	12
Figure S12. SIRT1, 2, 3, and 6 modulating assays of mariannamides A, B, C (1), and D (2).	12




Figure S1. ¹H NMR spectrum of mariannamide C (**1**) in CDCl₃ (500 MHz).




Figure S2. ^{13}C NMR spectrum of mariannamide C (**1**) in CDCl_3 (125 MHz).




Figure S3. ^1H - ^1H COSY spectrum of mariannamide C (**1**) in CDCl_3 .




Figure S4. HSQC spectrum of mariannamide C (**1**) in CDCl_3 .




Figure S5. HMBC spectrum of mariannamide C (1) in CDCl₃.




Figure S6. ^1H NMR spectrum of mariannamide D (2) in CDCl_3 (500 MHz).




Figure S7. ^{13}C NMR spectrum of mariannamide D (**2**) in CDCl_3 (125 MHz).




Figure S8. ^1H - ^1H COSY spectrum of mariannamide D (**2**) in CDCl_3 .




Figure S9. HSQC spectrum of mariannamide D (**2**) in CDCl_3 .




Figure S10. HMBC spectrum of mariannamide D (**2**) in CDCl_3 .




Figure S11. Selected 2D NMR correlations for mariannamide D (**2**).




Figure S12. SIRT1 (10 nM), 2 (17.5 nM), 3 (10 nM), and 6 (50 nM) modulating assay of mariannamides A (**A**), B (**B**), C (**1**), D (**2**) (50 μM), and nicotinamide (NAM, 1 mM) using a peptide substrate, SFP3 (2.5 μM). Values are expressed as percentages relative to the DMSO-treated well. Data are presented as mean \pm S.D. (n = 3). Statistical significance was examined using the Bonferroni-type multiple *t*-test by using GraphPad Prism6: **P* < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001 compared to the DMSO-treated well.